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1. Introduction 
Viral myocarditis, the inflammation of the myocardium caused by viral infection, is an 
important cause of dilated cardiomyopathy (DCM) – a major cause of morbidity and 
mortality worldwide (Mason, 2003; Esfandiarei & McManus, 2008; Cooper, 2009). In North 
America, viral myocarditis and DCM together account for 20% of the sudden deaths and 
heart failure in children and adolescents (Okuni et al., 1975; Drory et al., 1991). To date, there 
is no effective therapeutic against these diseases. Patients diagnosed with late stage DCM 
are limited to supportive treatments such as ventricular assist device implantation and heart 
transplantation.  
The clinical presentation of viral myocarditis comes in various severities. Most people have 
contracted and subsequently recovered from multiple viral infections of the heart without 
overt symptoms. Yet, retrospective studies revealed that ~20% of subclinical cases later 
develop congestive heart failure. In addition, some may experience acute fulminant viral 
myocarditis or persistent chronic myocarditis symptoms. About one-third of these patients 
with viral myocarditis subsequently develop DCM (Esfandiarei & McManus, 2008). A 
combination of new diagnostic technologies for viral myocarditis such as cardiovascular 
magnetic resonance techniques with conventional diagnostics including clinical 
presentation, histopathological examination, cardiac antibody assessment, and viral 
polymerase chain reaction (PCR), now helps better define disease stage and its respective 
management protocol (Baughman, 2006).  
The presence of viral genome in the myocardium is associated with significantly worse 
outcome over two years (Why et al., 1994). Analysis of human failing hearts by PCR 
unveiled trails of previous viral infection. The identified viruses include enterovirus, 
adenovirus, parvovirus B19, herpes simplex virus 6, cytomegalovirus, hepatitis C virus, and 
human immunodeficiency virus, which are clinically associated with viral myocarditis 
(Grist & Reid, 1997; Calabrese et al., 2010). Among them, coxsackievirus B3 (CVB3), an 
enterovirus in the picornavirus family, is highly implicated in clinical cases of viral 
myocarditis, particularly in neonates and young children, and is the most thoroughly 
studied causative agent in experimental viral myocarditis models (Froeschle et al., 1966; 
Abelmann, 1971; Reyes & Lerner, 1985; McManus et al., 1988). CVB3 replicates rapidly in 
short infection cycles that begin with viral receptor engagement and subsequent 
internalization, followed by translation of viral RNA, amplification of viral genome, viral 
assembly, and complete with viral progeny release.  
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CVB3 infection of myocarditis susceptible mice results in severe heart failure. The disease 
progression of viral myocarditis in the experimental infection model can be classified into 
three phases: acute (viremia), subacute (inflammatory), and chronic (remodeling) phases. 
The acute (viremia) phase is signified by active viral replication and direct virus-induced 
cardiomyocyte damage. The subacute (inflammatory) phase is characterized by the 
infiltration of immune cells that helps viral clearance but nonetheless adds to myocardial 
damage. The chronic (remodeling) phase is featured by the continual efforts of the impaired 
heart to meet the hemodynamic demand by remodeling the myocardium. Cardiac 
hypertrophy is triggered during remodeling to compensate for reduced contractile function 
due to myocyte loss and interstitial fibrosis in the earlier phases. However, such an adaption 
is unsustainable in the longer term in face of increasingly hostile environments, i.e. reduced 
blood supply and increased reactive oxidative stress, thus leading to cardiomyocyte death 
and triggering further inflammation and fibrosis. The pathological remodeling process 
eventually leads to DCM and heart failure.  
This book chapter focuses on the virus-host protein interactions in cardiomyocytes during 
viral myocarditis. We discuss the role of virus-induced protein cleavage and dysregulation 
of the host protein degradation systems in the pathogenesis of viral myocarditis and its 
subsequent progression to DCM.  
2. Host protein cleavages by coxsackieviral proteases contributing to cardiac 
dysfunction 
2.1 Viral proteases and dilated cardiomyopathy 
CVB3 encodes two viral proteases, 2A and 3C, both of which are cysteine proteases that 
have chymotrypsin-like activity and play critical roles in successful viral replication (Chau et 
al., 2007). First, the viral proteases are required to process the large viral polyprotein, a 
product of mono-cistronic translation of RNA genome, into the individual functional, 
structural and non-structural proteins. Second, the viral proteases facilitate viral replication 
by cleaving a number of host proteins that are involved in various cell functions such as 
transcription, translation, cell signaling, and cellular structure. 
Viral myocarditis is originally thought to be an immune response driven disorder. The 
initial observation that established the importance of direct virus-mediated myocardial 
damage in the pathogenesis of viral myocarditis was made in severe combined 
immunodeficient (SCID) mice, which lack functional T and B lymphocytes and yet 
developed early and severe myocyte damage upon enterovirus challenge (McManus et al., 
1993). The significance of viral proteins in the development of viral myocarditis and DCM 
was further explored by Dr. Knowlton’s research group. First, they showed that the cardiac-
specific expression of a replication-restricted CVB3 mutant genome in transgenic mice, 
which only allows the expression of viral proteins without generating viral progenies and 
subsequent immune response, results in DCM phenotype (Wessely et al., 1998). Then, they 
demonstrated that mice with cardiac-restricted expression of viral protease 2A display a 
severe DCM phenotype (Xiong et al., 2007). These findings suggest that viral proteases play 
an important role in the development of viral-induced dilated cardiomyopathy. 
2.2 Cleavage of dystrophin during CVB3 infection may contribute to dilated 
cardiomyopathy  
The observation that mouse cardiac expression of viral protease 2A induces DCM has been 
explained based on the landmark finding that dystrophin, which links the cytoskeleton to 
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the extracellular matrix (ECM) by forming the dystrophin glycoprotein complex (DGC), is 
cleaved during CVB3 infection by protease 2A (Badorff et al., 1999; Badorff & Knowlton, 
2004) (Fig. 1A). Dystrophin has three domains that serve different purposes. Its N-terminal 
domain anchors to the actin cytoskeleton and its rod domain provides the linkage to the C-
terminal domain, which binds to -dystroglycan that in turn connects to the sarcolemma 
and the extracellular matrix (Fig. 1A). Furthermore, dystrophin-deficient mice have been 
shown to have an increased susceptibility to viral myocarditis and develop severe 
cardiomyopathy (Xiong et al., 2002). Human genetic mutations of the dystrophin gene cause 
Duchenne Muscular Dystrophy (DMD) (Nigro et al., 1990). Approximately 20% of DMD 
patients suffer and die from a resultant cardiomyopathy. Other mutations of the dystrophin 
gene also cause X-linked DCM (Ferlini et al., 1999). CVB3-induced dystrophin cleavage 
occurs at its 3’ hinge and therefore breaks its connection to the ECM. As a result, the 
sarcolemmal integrity is compromised and force transmission is reduced. This can further 
lead to cardiomyocyte necrosis due to the increased sarcolemmal permeability (Fig. 1A). 
Thereafter, dystrophin cleavage has been viewed as a major mechanism in enteroviral 
cardiomyopathy. However, dystrophin knockout mice (Mdx) display only mild 
cardiomyopathy phenotype, due to the compensatory upregulation of utrophin, a 
dystrophin homologue (Deconinck et al., 1997; Grady et al., 1997). Thus, other mechanisms 
may also contribute to the severe cardiomyopathy phenotype in viral protease 2A 
expressing mice.  
2.3 Cleavage of serum response factor by viral protease 2A is associated with 
impaired cardiac function  
Recent efforts have demonstrated for the first time that serum response factor (SRF) is 
cleaved in CVB3-infected mouse hearts and cultured murine cardiomyocytes (unpublished). 
SRF, which belongs to the MADS-box (MCM1, Agamous, Deficiens, and SRF) protein 
superfamily, is a muscle-enriched transcription factor that regulates the expression of 
contractile and regulatory genes, as well as microRNAs (miRNAs) (Miano, 2003; Niu et al., 
2007; Oka et al., 2007) (Fig. 1B). SRF interacts with tissue specific cofactors such as 
myocardin, Nkx2.5, c-Fos, and binds to the serum response element (SRE) of its target genes. 
It contains two major domains: the N-terminal DNA binding and dimerization domain and 
the C-terminal transactivation domain (Fig. 1B). Genomic studies have identified over 1200 
SRE containing genes and more than 250 of these have been verified (Sun et al., 2006). 
Cardiac contractile genes under SRF regulation include cardiac -actin, -myosin heavy 
chain, myosin light chain, cardiac troponin I, etc. SRF is indispensable for mesoderm 
formation and plays a central role in cardiac development and function (Niu et al., 2007). 
Therefore, SRF knockout results in embryonic lethality (Parlakian et al., 2004). The 
construction of cardiac-specific inducible SRF knockout transgenic mice overcomes this 
problem and helps illustrate the importance of SRF in cardiac function (Parlakian et al., 
2005). It was shown that SRF knockout in the adult mouse heart results in damaged cardiac 
function, and subsequent progression to DCM. Genetic mutations of SRF in humans have 
not been described likely due to the associated lethality. However, the expression of 
alternatively spliced SRF isoforms, which was shown to have inhibitory effects on wild-type 
SRF, is increased in failing human and animal hearts (Davis et al., 2002). Furthermore, a 
cleaved form of SRF lacking the transactivation domain was also found in human failing 
hearts as a result of caspase-3 activation during cardiomyocyte apoptosis (Chang et al., 
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2003). This caspase-cleaved SRF fragment functions as a dominant-negative mutant that 
inhibits SRF-dependent activation of cardiac genes. On the other hand, SRF overexpression 
in transgenic mouse hearts leads to the development of cardiac hypertrophy and subsequent 
cardiomyopathy (Zhang et al., 2001).  
During CVB3 infection, SRF is cleaved into a ~47kD N-terminal fragment (SRF-N) and a 
~20kD C-terminal fragment (SRF-C) by viral protease 2A (unpublished). As a result, the 
DNA-binding domain is detached from the transactivation domain, thus abolishing SRF 
function. In addition, the SRF-N fragment generated from the cleavage can compete with 
wild-type SRF for target gene binding, and thereby exhibits dominant-negative suppression 
of SRF target gene expression (Fig. 1B). This study suggests another important mechanism 
by which CVB3 damages cardiac function and leads to subsequent DCM. Further research 
using knock-in transgenic mice expressing non-cleavable SRF will help clarify the relative 
contribution of SRF cleavage in the pathogenesis of viral myocarditis.  
2.4 Caspase activation by viral proteases  
Both viral proteases 2A and 3C lead to late onset of host cell apoptosis through the direct 
cleavage of caspase-8 and the activation of caspase-3, as well as the cleavage of anti-
apoptotic protein Bid that leads to mitochondrial cytochrome c release and subsequent 
initiation of the caspase cascade (Chau et al., 2007). Cardiomyocyte apoptosis is a common 
phenomenon in various cardiac diseases. Apoptosis, also known as programmed cell death, 
is the self-destruction pathway activated when host cells decide to commit suicide. 
Apoptosis during viral myocarditis caused by viral protease-induced caspase activation, 
however, is “switched on” intentionally by viral mechanisms for the release of mature viral 
progenies. In cell culture, caspase activation results in cytoplasmic proteolysis and DNA 
fragmentation. However, despite ultrastructural evidence of cytochrome c release detected 
in many cardiomyocytes of heart failure patients, intact nuclei are seen in all of these 
myocytes (Narula et al., 1998). This suggests that the terminally differentiated 
cardiomyocytes have evolved strategies to resist nuclear fragmentation despite ongoing 
cytoplasmic apoptosis. In fact, the number of apoptotic myocytes in a cardiomyopathic heart 
ranges only from 0.07% to 0.7% as compared to 0.003% in the normal myocardium (Narula 
et al., 1998). Nevertheless, cytoplasmic apoptosis initiated during viral myocarditis may 
compromise mitochondrial ATP generation, as well as cause destruction to contractile 
proteins which add to systolic dysfunction in the disease pathogenesis. 
2.5 Other mechanisms 
Other mechanisms that viral proteases use to impair cardiomyocyte function include the 
interference of host gene transcription by the cleavage of cyclic AMP response element 
binding protein (CREB) (Yalamanchili et al., 1997), the disruption of host protein translation 
through the cleavage of eukaryotic translation initiation factor 4 (eIF4) (Chau et al., 2007) 
and eIF5B (de Breyne et al., 2008), the interception of cell signaling pathways via the 
cleavage of RasGAP (Huber et al., 1999), and the weakening of the cytoskeletal network by 
the cleavage of cytokeratin-8 (Seipelt et al., 2000). Although there are no known cardiac 
diseases associated with the aforementioned proteins, their cleavages exert additive effects 
to the final detriment of the infected cardiomyocytes.  
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Fig. 1. Host protein cleavages by coxsackieviral proteases in viral myocarditis.  
A. Coxsackieviral protease 2A cleaves dystrophin at its 3' hinge. Dystrophin is a component 
of the dystrophin-glycoprotein complex that links the cytoskeleton to the extracellular 
matrix. Dystrophin cleavage contributes to myocyte dysfunction by reducing contractile 
force transmission and increasing sarcolemmal permeability.  
B. Viral protease 2A also cleaves serum response factor (SRF). SRF is a muscle-enriched 
transcription factor that regulates the expression of cardiac regulatory proteins, sarcomere 
contractile proteins, as well as cardiac-specific microRNAs (miRNAs). SRF associates with 
co-factors such as GATA4, Nkx2.5, MEF2, and myocardin and binds to serum response 
element (SRE) (also known as CArG box) to activate gene transcription. SRF cleavage results 
in myocyte dysfunction by the dissociation of the N-terminal DNA binding/dimerization 
domain from the C-terminal transcriptional activation domain, thus abolishing SRF-
mediated gene expression. Furthermore, the N-terminal fragment (SRF-N) exhibits a 
dominant-negative effect on endogenous SRF function by competing for DNA binding. 
the heart 
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3. Dysregulation of host protein degradation systems in viral cardiomyopathy  
3.1 Protein degradation systems  
Protein degradation is an integral part in the maintenance of cellular homeostasis. It allows 
for the selective removal of host proteins that are misfolded, damaged, and unnecessary, 
and balances the ongoing protein synthesis that is driven to provide the desirable cellular 
function in response to environmental changes. The dynamic interaction between protein 
synthesis and degradation is of particular importance to cardiomyocytes, the basic 
contractile units of the heart, due to the plasticity of the heart. It drives the hypertrophy or 
atrophy of individual cardiomyocytes, which contributes to sufficient contractile force 
generation that meets the hemodynamic demands. Consequently, the dysregulation of 
protein degradation jeopardizes cardiomyocyte vitality and function and plays an important 
role in the development of various cardiac diseases (Zheng & Wang, 2010).  
Enteroviral infection leads to the dysregulation of host protein degradation pathways, 
which include the ubiquitin/proteasome system (UPS) and autophagy. Such viral-induced 
manipulation plays key roles not only in viral propagation, but also in the pathogenesis of 
viral myocarditis and the subsequent development of DCM. The following sections discuss 
the contributions of UPS and autophagy in viral propagation and the development of 
cardiomyopathy. 
3.2 The ubiquitin/proteasome system  
The ubiquitin/proteasome system is the major protein degradation pathway in eukaryotic 
cells that accounts for ~80% of host protein recycling (Zheng & Wang, 2010). By controlling 
the longevity/half-life of most proteins (predominantly short-lived but also some long-lived 
proteins), the UPS extends its role beyond protein recycling and regulates most aspects of 
cellular functions. UPS substrate selectivity is achieved by protein polyubiquitination, i.e. 
the attachment of ubiquitin (Ub) molecules onto the target protein. Ubiquitin is a small 76 
amino acid protein modifier molecule that conjugates to target protein or to another Ub 
through one of its seven lysine residues. Ubiquitin linkage at different lysine residues serves 
different functions. For example, polyubiquitination via lysine 48 targets protein for UPS 
degradation, polyubiquitination via lysine 63 promotes signal transduction or targets 
degradation through the autophagy pathway, whereas monoubiquitination modulates 
protein intracellular localization and protein function.  
Protein ubiquitination is regulated in a multi-step manner (Hershko & Ciechanover, 1998) 
(Fig. 2A). First, Ub is activated by the ubiquitin-activating enzyme (E1) using ATP. Then, it 
is transferred to ubiquitin-conjugating enzyme (E2). Finally, it is conjugated onto the target 
protein selectively brought in by the ubiquitin ligase (E3). A polyUb chain is formed by 
repeating the ubiquitination process. The expression of these important enzymes that 
regulate protein ubiquitination may change according to physiological stimuli. For instance, 
in cardiac atrophy mouse model, the E2 enzyme UbcH2 expression is upregulated in 
atrophic hearts to increase the capacity of protein degradation (Razeghi et al., 2006). 
The 26S proteasome is composed of the 20S proteolytic core and the 19S proteasome 
activator lid(s) (Luo et al., 2010). The 20S proteolytic core is made up of two outer (┙-
subunits) and two inner (┚-subunits) rings. It contains caspase-like, trypsin-like, and 
chymotrypsin-like protease activities conveyed by subunits ┚1, ┚2, and ┚5, respectively. The 
19S lid(s), also known as proteasome activator 700 (PA700), helps the recognition and 
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docking of polyubiquitinated target protein. 19S also serves to detach and hence recycle the 
Ub by its deubiquitinating enzyme (DUB) activity. Furthermore, 19S unfolds the target 
protein and feeds it to the 20S core for degradation.  
The immunoproteasome is an alternative version of the proteasome expressed to 
accommodate inflammatory responses upon stimulation with interferon- (Rivett & Hearn, 
2004). The immunoproteasome has a 20S core that substitutes the constitutive catalytic ┚-
subunits with inducible ┚-counterparts (┚1i, ┚2i, and ┚5i), which offer different proteolytic 
function and activity to generate small peptides suitable for antigen presentation by major 
histocompatibility complex (MHC) class I (Griffin et al., 1998) (Fig. 2A). In addition to the 
19S proteasome, the immunoproteasome can also have a different lid(s) – the 11S 
proteasome, also known as PA28 (proteasome activator 28). Different compositions of 11S 
exist: heteroheptamer of PA28 and PA28 that are induced by interferon- under 
intensified immune response (Murray et al., 2000) and homoheptamer of PA28 that resides 
in the nucleus and assists ATP- and ubiquitin-independent proteasomal activity (Mao et al., 
2008). Sometimes, hybrid proteasomes with both 11S and 19S lids are also observed. 
However, their functions remain to be explored.  
3.2.1 The UPS and heart diseases 
UPS dysregulation is a common phenomenon in heart diseases. It is accentuated with the 
accumulation of Ub-protein conjugates and is associated with markedly reduced proteasome 
proteolytic activity in failing human hearts as compared to non-failing hearts (Predmore et al., 
2010). This suggests that ubiquitinated proteins in hearts are not degraded due to impaired 
proteasomal function. While no changes were noted in protein expression of proteasome 
subunits (i.e. 20S, 19S, 11S), elevated levels of protein carbonyls and 4-hydroxynonenylated 
proteins were observed in failing hearts. Also, oxidative modification to the 19S ATPase 
subunit Rpt5 was found in these failing hearts. Together, these oxidative modifications to 
proteasome subunits and substrate proteins may lead to impaired proteasomal function. On 
the other hand, microarray studies demonstrate reduced transcript levels of some 20s ┙- and 
┚-subunits in the failing hearts as compared to controls (Hwang et al., 2002; Kaab et al., 2004). 
The incongruence between protein and mRNA expression of proteasome subunits may be 
attributed to myocyte loss and fibrosis in the failing hearts.  
Animal models of cardiac diseases also have an increased ubiquitinated protein expression, 
but are acommpanied with changes in their proteasome expression profile. Upregulation in 
protein expression of proteasome subunits was observed in a left ventricular hypertrophy 
mouse model (Depre et al., 2006). Post-translational modifications of the proteasome 
subunits were also reported in these hypertrophic hearts (Depre et al., 2006). Treatment with 
proteasome inhibitor effectively prevents cardiac hypertrophy development, suggesting that 
the upregulation of proteasome expression is central to this physiological adaptation. 
Similar beneficial effects of proteasome inhibition in the regression of cardiac hypertrophy 
were observed in other studies (Meiners et al., 2008; Stansfield et al., 2008). Besides 
hypertrophic cardiomyopathy, the accumulation of Ub-conjugated proteins was observed in 
hyperglycemia-induced cardiomyopathy mouse model (Powell et al., 2008). A parallel drop 
in the basal ATP-dependent proteasomal activity was observed in these mice. However, an 
increased ATP-independent chymotryptic proteasomal activity was observed, which is 
accompanied by an increased expression of 11S lid subunits PA28 and PA28, as well as 
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the 20S subunits 3 and 5. Together, these data suggest a shift to immunoproteasomal 
activity is induced under hyperglycemic stress conditions to help the degradation of 
accumulated proteins.  
The difference in cardiac proteasome expression profiles between human heart failure and 
various cardiomyopathy mouse models can be attributed to the limited time frame of 
animal studies. It is likely that stressed human hearts also induce the compensatory 
upregulation of proteasomal expression and activity at the earlier disease stages, but fail to 
maintain these changes over time.   
3.2.2 The UPS and viral myocarditis 
The UPS is also dysregulated in viral myocarditis (Fig. 2A). Accumulation of Ub-protein 
conjugates, as in other cardiomyopathies, was observed in CVB3-infected mouse hearts and 
cultured cells (Luo et al., 2003; Gao et al., 2008; Si et al., 2008). The expression of several 
enzymes in the UPS pathway such as E1 enzyme E1A/E1B, E2 enzyme UbcH7, and DUB 
UCHL1 (ubiquitin carboxyl-terminal hydrolase L1) is upregulated in CVB3-infected mouse 
hearts, while ATP-dependent proteasomal activity is unaltered (Gao et al., 2008). In vitro 
application of proteasome inhibitors such as MG132 (Luo et al., 2003), lactacystin (Luo et al., 
2003), pyrrolidine dithiocarbamate (PDTC) (Si et al., 2005), and curcumin (Si et al., 2007) 
effectively attenuates viral RNA replication and protein synthesis. In addition, depletion of 
Ub by RNA interference also inhibits viral replication (Si et al., 2008). Furthermore, it was 
shown that viral RNA-dependent polymerase 3D is ubiquitinated during viral replication, 
which may help its anchorage to intracellular membrane platforms required for the 
assembly of viral RNA replication machinery (Si et al., 2008). In vivo administration of 
proteasome inhibitor to CVB3-infected mice also improves the outcome of viral myocarditis 
with reduced myocardial damage and inflammatory infiltration (Gao et al., 2008). The viral 
titer, however, is not significantly reduced in the treated mice. This suggests that 
proteasome inhibitor treatment ameliorates viral myocarditis via multiple mechanisms: 
direct viral inhibition and immunomodulation. It was further demonstrated that the 
expression of 11S subunit PA28 plays a role in CVB3 replication (Gao et al., 2010). CVB3 
infection leads to the redistribution of PA28 from the nucleus to the cytosol, where it 
interacts with host proteins, such as tumor suppressor protein p53, and promotes their 
degradation via UPS. Overexpression of PA28 enhances viral replication while its 
knockdown does the opposite.  
Szalay et al. explored the involvement of the immunoproteasome in viral myocarditis. They 
found that the catalytic subunits of the immunoproteasome, LMP2 (┚1i), LMP7 (┚5i), and 
MECL-1 (┚2i), are upregulated in CVB3-infected myocarditis-susceptible mouse hearts as 
compared to infected hearts from resistant mouse strains (Szalay et al., 2006). Increased 
activity of the immunoproteasome in the susceptible myocardium helps generate the MHC 
class I-restricted peptide, boost antigen presentation and mount the subsequent adaptive 
immune response. A recent study demonstrates a differential immunoproteasome 
expression pattern between myocarditis-susceptible and -resistant mouse strains (Jakel et al., 
2009). In this study, immunoproteasome formation peaks early after CVB3 challenge in 
resistant mice, while it is postponed and expressed in greater extent in susceptible mice. The 
timing and magnitude of immunoproteasome activation determine in part the effectiveness 
of early viral clearance and the extent of direct viral-mediated damages, as well as the injury 
incurred during adaptive immune responses.  
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3.3 Autophagy  
The other host protein degradation system is autophagy, i.e. “self-eating”. It proceeds by the 
engulfing of a portion of the cytoplasm including long-lived and misfolded proteins and 
organelles by the autophagic membranes to form double-membraned vesicles called 
autophagosomes, followed by their delivery to lysosomes for degradation (Levine & 
Kroemer, 2008) (Fig. 2B). Autophagy is activated in two parallel cascades of enzymatic 
actions that are similar to the process of protein ubiquitination (Ravikumar et al., 2010). First, 
Atg12 (autophagy-related gene 12) and Atg8 (also known as LC3, microtubule-associated 
protein light chain 3, in mammalian cells) are activated by the E1-like activating enzyme 
Atg7 using ATP. Then, Atg12 is conjugated to its E2 Atg10, while Atg8 is attached to 
another E2 Atg3. Atg12 is then transferred to its designated partner Atg5 forming the Atg12-
Atg5 complex and further matures by the conjugation to Atg16. Finally, the Atg12-Ag5-
Atg16 complex acts as an E3 to help Atg8 lipidation, forming the Atg8-PE 
(phosphatidylethanolamine) complex. Lipidation of Atg8 helps its incorporation onto the 
autophagic membrane. Atg8-PE then takes part in the elongation of the autophagic 
membrane and its enclosure to form the autophagosome.   
3.3.1 Autophagy and cardiac diseases  
Under baseline conditions, autophagy represents an important homeostatic mechanism. 
However, excessive activation of the autophagy machinery has been suggested to be 
involved in the pathogenesis of various disease conditions, including cardiac diseases. LC3 
activation was observed early and was well-sustained in pressure-overload cardiomyopathy 
mouse model (Zhu et al., 2007). Autophagy activation in this model promotes cardiac 
remodeling. Overexpression of Beclin-1, also known as Atg6, accentuates pathological 
remodeling and interstitial fibrosis, whereas heterozygous knockout of Beclin-1 improves 
systolic function and delays cardiac remodeling. In desmin-mediated cardiomyopathy 
mouse model, early activation of autophagy was observed well before any measurable 
decline in cardiac function (Tannous et al., 2008). Autophagy pathway impairment by 
heterozygous inactivation of Beclin-1 leads to accumulation of polyubiquitinated protein 
aggregates, as well as acceleration to heart failure and early mortality (Tannous et al., 2008). 
Similarly, autophagy is activated in both ischemia and subsequent reperfusion, but via two 
different initiation pathways (Takagi et al., 2007). The AMPK pathway drives autophagy 
during ischemia, while Beclin-1 initiates autophagy upon reperfusion. Autophagy during 
ischemia is considered a cell survival response as it helps to sustain the starved 
cardiomyocytes during ischemia; however, autophagy during reperfusion is viewed as a 
pathological response as it promotes autophagic cell death.  
3.3.2 Autophagy and viral myocarditis 
Autophagy also plays an important part in the host innate defense system by direct 
sequestration of invading pathogens (bacteria, fungi, and virus) for clearance through 
lysosomal degradation (Jackson et al., 2005). In addition, autophagy helps antigen 
presentation to class II MHC in order to mount an adaptive immune response (Dengjel et al., 
2005). However, this innate defense machinery is subverted by certain viruses to facilitate 
their replication (Jackson et al., 2005; Wong et al., 2008). It was shown that LC3-PE 
expression, a hallmark of autophagosome formation, is increased after CVB3 infection with 
dramatic reorganization of intracellular membranes (Wong et al., 2008) (Fig. 2B). Inhibition 
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of autophagy by 3-methyladenine which targets the upstream signaling class III PI3-kinase, 
and by siRNA knockdown of Atg7 expression effectively block viral replication (Wong et al., 
2008). Recent work in mouse models also suggests that autophagy is activated in vivo after 
CVB3 infection (unpublished data). LC3-PE expression is elevated in CVB3-infected organs 
such as the heart, liver, and pancreas. Kemball et al. also reported the induction of 
autophagosome formation in pancreatic acinar cells in CVB3-infected mice (Kemball et al., 
2010). This theme of virus-induced autophagy activation is further extended to 
coxsackievirus B4-infected rat primary neurons (Yoon et al., 2008). Nonetheless, virus-
induced autophagy only serves to help viral replication without increasing protein 
degradation as suggested by the unchanged expression level of p62, a selective autophagy 
substrate, after virus infection (Wong et al., 2008).  
Subversion of the autophagy machinery by enteroviruses may contribute to the 
pathogenesis of viral myocarditis beyond impacting cardiomyocyte viability. Recent 
research demonstrates that cellular autophagy plays a role in nucleic acid-sensing toll-like 
receptor 3 (TLR3) signaling, which is necessary for the antiviral interferon pathway (Gorbea 
et al., 2010). TLR3-deficient mice show vulnerability to CVB3 infection and develop acute 
myocarditis (Negishi et al., 2008). Dysregulation of the autophagy pathway in CVB3-infected 
cardiomyocytes may interfere with TLR3-mediated antiviral response, resulting in 
compromised viral clearance and increased myocardial damage during viremia. In addition, 
autophagy is known to be a pro-survival response against apoptosis. The dysregulation of 
autophagy may decrease the viability of virus-infected cardiomyocytes because it cannot 
protect the host from virus-induced apoptosis. Furthermore, angiotensin II receptors type I 
& II (AT1 & AT2) regulate cardiomyocyte autophagy activity (Porrello et al., 2009). AT1 
expression triggers autophagy in neonatal cardiomyocytes as well as subsequent autophagic 
cell death, while AT2 expression counteracts AT1-induced autophagic activity. Further 
modulation by angiotensins may have an adverse effect on virus-infected cardiomyocytes as 
it may further activate autophagy, thus triggering autophagic cell death.  
4. Potential therapeutics targeting viral proteases, UPS, and autophagy   
The current knowledge of the roles of viral proteases and the host protein degradation 
systems in viral myocarditis may lead to new diagnostic and therapeutic approaches for the 
disease. Virus-induced SRF cleavage fragments may be utilized as a biomarker to detect 
acute phase myocarditis. Early diagnosis of viral myocarditis opens up the optimal 
timeframe for treatment. Successful medical interventions during acute infection can limit 
viral replication and its associated damage, limit viral spreading, as well as minimize the 
damage caused by immune activation. Since the viral proteases and the protein degradation 
systems all play important roles in viral propagation, a combinatorial therapy of highly 
specific viral protease inhibitors, proteasome inhibitors, and autophagy inhibitors during 
viremia would limit viral infection effectively. Furthermore, application of proteasome 
inhibitors and autophagy inhibitors provides additional benefits in immunomodulation to 
control the inflammatory response. On the other hand, viral myocarditis patients in the 
chronic phases may be managed differently. Since DCM patients have depressed 
proteasomal function, proteasome inhibitor treatment may further exacerbate myocardial 
damage. Moreover, long-term application of inhibitors against UPS will have adverse effects 
as demonstrated in the increased incidence of heart failure in cancer patients undergoing 
proteasome inhibitor treatment (Enrico et al., 2007; Hacihanefioglu et al., 2008).  
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Fig. 2. Dysregulation of the host protein degradation systems in viral cardiomyopathy.  
The ubiquitin/proteasome system (UPS) and autophagy are the two major protein 
degradation mechanisms in eukaryotic cells. A. The UPS function by a cascade of enzymatic 
reactions (El - ubiquitin activating enzyme, E2 - ubiquitin conjugating enzyme, E3 - 
ubiquitin ligase) that conjugate ubiquitin, a small protein modifier, onto the target proteins. 
The type of ubiquitin conjugation linkage determines the target protein’s fate: functional 
modulation or degradation. Polyubiquitinated target proteins are recognized by the 26S 
proteasome for degradation, whereas monoubiquitination serves to help endocytosis, 
endosomal sorting, DNA repair, histone regulation, and nuclear export. Ubiquitins are 
recycled by the deubiquitinating enzymes (DUBs). CVB3 infection causes the dysregulation 
of the UPS. An increased expression of ubiquitin-protein conjugates, E1A/E1B (El), UbcH7 
(E2), UCH-L1 (DUB) was observed  in CVB3-infected mouse hearts. Proteasome inhibitor 
application attenuates viral replication in vitro and reduces myocardial lesion and fibrosis in 
vivo. B. Autophagy begins with the enwrapping of organelles and cytoplasmic proteins by 
the isolation membrane which elongates and encloses to form a double-membraned vesicle 
called the autophagosome. The autophagosome fuses with lysosomes to degrade the 
sequestrated materials. Autophagy plays an important role in host defense by trapping and 
degrading invading pathogens. However, certain viruses including CVB3 evolve strategies 
to subvert autophagic mechanism to facilitate their own replication. Autophagosome 
formation is upregulated during CVB3 infection. Inhibition of the autophagy pathway has 
been shown to block viral replication in vitro. 
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5. Conclusion 
Viral-induced protein cleavage and host protein degradation dysregulation play important 
roles in the pathogenesis of viral myocarditis and its subsequent progression to DCM. 
Identification of viral-induced protein cleavage fragments may allow early diagnosis of viral 
myocarditis, which opens up the optimal treatment window. A combination of antiviral 
therapies including specific viral protease inhibitors, proteasome inhibitors, and autophagy 
inhibitors presents new strategies for effective early viral clearance and minimization of 
viral-induced, inflammation-associated damage. Further studies employing system-like 
approaches, such as ubiquitomics, degradomics, and RNAi screens, are required to decipher 
the complex interactions between host and virus during different stages of viral myocarditis. 
Efforts in clarifying the precise functions and regulatory mechanisms of the host protein 
degradation systems in the disease progression of viral myocarditis will lead to novel 
therapeutic targets to improve treatment in different disease stages.   
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